• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hepatic Encephalopathy - Pipeline Review, H1 2012 Product Image

Hepatic Encephalopathy - Pipeline Review, H1 2012

  • Published: April 2012
  • 46 pages
  • Global Markets Direct

Hepatic Encephalopathy – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Hepatic Encephalopathy - Pipeline Review, H1 2012', provides an overview of the Hepatic Encephalopathy therapeutic pipeline. This report provides information on the therapeutic development for Hepatic Encephalopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy. 'Hepatic Encephalopathy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatic Encephalopathy.
- A review of the Hepatic Encephalopathy products under development by READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy Overview
Therapeutics Development
An Overview of Pipeline Products for Hepatic Encephalopathy
Hepatic Encephalopathy Therapeutics under Development by Companies
Hepatic Encephalopathy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Hepatic Encephalopathy Therapeutics – Products under Development by Companies
Hepatic Encephalopathy Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hepatic Encephalopathy Therapeutics Development
Ocera Therapeutics, Inc.
Hyperion Therapeutic, Inc.
Hepatic Encephalopathy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HPN-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AST-120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OCR-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lactobacillus GG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rifaximin + Lactulose - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hepatic Encephalopathy Therapeutics – Drug Profile Updates
Hepatic Encephalopathy Therapeutics - Dormant Products
Hepatic Encephalopathy – Product Development Milestones
Featured News & Press Releases
Nov 04, 2011: Salix Previews Data Slated For Presentation At 62nd Annual Meeting Of The American Association For The Study Of Liver Diseases
Dec 15, 2010: Ocera Completes First In Human Studies With OCR-002 In Hyperammonemia And Hepatic Encephalopathy
Oct 30, 2010: Salix Previews Data On XIFAXAN For Treatment Of Hepatic Encephalopathy At AASLD 2010 Annual Meeting
May 26, 2010: XIFAXAN (Rifaximin) 550 mg Tablets Now Available In U.S. Pharmacies
May 20, 2010: Salix Announces Issuance Of U.S. Patent For Rifaximin
Feb 23, 2010: FDA Advisory Committee Recommends Approval Of XIFAXAN (Rifaximin) Tablets, 550 Mg For Maintenance Of Remission Of Hepatic Encephalopathy
Dec 03, 2009: Hyperion Therapeutics Enrolls First Patient In Phase II Hepatic Encephalopathy Trial
Nov 03, 2009: Salix Pharmaceuticals Secures Additional Intellectual Property Relating to Rifaximin
Oct 05, 2009: Salix Pharmaceuticals Acquires U.S. Right to Lupin's Proprietary Bioadhesive Technology for Extended Release Rifaximin Product
Sep 17, 2009: Hyperion Therapeutics Receives Orphan Drug Designation For HPN-100 For The Treatment Of Hepatic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hepatic Encephalopathy, H1 2012
Products under Development for Hepatic Encephalopathy – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Ocera Therapeutics, Inc., H1 2012
Hyperion Therapeutic, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hepatic Encephalopathy Therapeutics – Drug Profile Updates
Hepatic Encephalopathy Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Hepatic Encephalopathy, H1 2012
Products under Development for Hepatic Encephalopathy – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos